Skip to main content
. 2017 Apr 4;18:22. doi: 10.1186/s40360-017-0124-y

Fig. 1.

Fig. 1

Patient selection. *Pegvisomant was excluded from the analysis because it is not a somatostatin analog and the mode of treatment (daily injection) was not considered comparable to that of octreotide and lanreotide (monthly injection) for this study